Therapeutic Focus: <em>Drop</em>ping Some Knowledge
Vizz (aceclidine ophthalmic solution) 1.44%, from Lenz Therapeutics, offers spectacle-free vision and the opportunity to secure patient loyalty.
-
By
-
Julie Greenbaum, editor
-
January 1, 2026
-
Clinical Scorecard: Therapeutic Focus: Dropping Some Knowledge
At a Glance
| Category | Detail |
|---|
| Condition | Presbyopia |
| Key Mechanisms | Pupil-selective miotic action that contracts the iris sphincter muscle, enhancing depth of focus without myopic shift. |
| Target Population | Patients with presbyopia seeking spectacle-free vision. |
| Care Setting | Ophthalmology practices. |
Key Highlights
- Vizz (aceclidine ophthalmic solution) 1.44% improves near vision within 30 minutes.
- Provides functional vision across distance, intermediate, and near ranges.
- Enhances patient satisfaction and loyalty, leading to increased referrals.
- Offers a solution for presbyopic patients who wear contact lenses.
- Minimal side effects such as mild redness or burning upon instillation.
Guideline-Based Recommendations
Diagnosis
- Assess visual acuity and patient history to confirm presbyopia.
Management
- Consider Vizz as a treatment option for presbyopia to improve near vision.
Monitoring & Follow-up
- Monitor patient response to Vizz within 30 minutes of administration.
Risks
- Inform patients about potential mild side effects like redness or burning.
Patient & Prescribing Data
Presbyopic patients, including those who wear contact lenses.
Vizz can be used alongside contact lenses for improved near vision without the need for reading glasses.
Clinical Best Practices
- Manage patient expectations regarding potential side effects.
- Tailor solutions to individual patient needs to enhance satisfaction.
- Encourage referrals by providing effective treatment options.
Related Resources & Content
